We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

EKF Molecular Highlights Ultra-Sensitive Cancer Mutation Detection Kits

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

EKF Diagnostics will be present on Booth #438 at AACR 2014 (American Association of Cancer Research), 5-9th April, San Diego.

EKF Molecular will exhibit its PointMan™ DNA-enrichment technology which enables ultra-sensitive and highly-specific cancer mutation detection unmatched by existing technologies.

PointMan is an extremely sensitive and selective tool based on real-time PCR technology offering the ability to enrich mutations from limited sample material. This is vital for a companion diagnostic particularly in the field of oncology, where availability of tumour biopsy tissue is restricted.

In collaboration with Swansea University, EKF Molecular is currently investigating the ability of PointMan kits to enrich mutant DNA from a blood-based sample. Initial results have demonstrated the detection of gene mutations in blood from samples archived in the Wales Cancer Bank.

EKF Molecular has a growing range of products and technologies developed to meet an increasing demand for superior sensitivity and specificity in molecular diagnostics.

PointMan DNA enrichment kits are available to detect a variety of mutations for cancer biomarkers including: BRAF, KRAS, EGFR, NRAS and JAK2. These genes are associated with skin melanoma, colorectal and lung cancers, as well as myeloma.